Related references
Note: Only part of the references are listed.Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential
Roland H. Stauber et al.
CANCER RESEARCH (2007)
Targeting survivin in cancer therapy: fulfilled promises and open questions
Marzia Pennati et al.
CARCINOGENESIS (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study
Ioannis Rouvelas et al.
WORLD JOURNAL OF SURGERY (2006)
Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma
S. Mega et al.
DISEASES OF THE ESOPHAGUS (2006)
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer
H Xi et al.
CLINICAL CANCER RESEARCH (2005)
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer - implications for response classification
PM Schneider et al.
ANNALS OF SURGERY (2005)
Survivin, a potential biomarker in the development of Barrett's adenocarcinoma
D Vallböhmer et al.
SURGERY (2005)
Neoadjuvant chemotherapy for epithelial ovarian cancer - role of apoptosis
T Dutta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Y Wang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis
SE Greer et al.
SURGERY (2005)
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence
H Pohl et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Current and ongoing progress in the therapy for resectable esophageal cancer
CR Thomas
DISEASES OF THE ESOPHAGUS (2005)
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
A Chakravarti et al.
ONCOGENE (2004)
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma:: results of a prospective phase-II trial
BLDM Brücher et al.
EJSO (2004)
Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy:: criteria of the histopathological evaluation
SE Baldus et al.
PATHOLOGE (2004)
Expression of IAP family proteins in esophageal cancer
T Nemoto et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2004)
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma
P Grabowski et al.
BRITISH JOURNAL OF CANCER (2003)
Apoptotic and proliferative indexes in esophageal cancer: Predictors of response to neoadjuvant therapy apoptosis and proliferation in esophageal cancer
DA Beardsmore et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2003)
Multimodality therapy for esophageal cancer
Y Refaely et al.
SURGICAL CLINICS OF NORTH AMERICA (2002)
Analysis of reduced death and complication rates after esophageal resection
BP Whooley et al.
ANNALS OF SURGERY (2001)
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma
SG Urba et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Survivin as a radioresistance factor in pancreatic cancer
K Asanuma et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2000)
Structural basis for phosphoserine-proline recognition by group IVWW domains
MA Verdecia et al.
NATURE STRUCTURAL BIOLOGY (2000)
Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years
N Ando et al.
ANNALS OF SURGERY (2000)
Share Paper
